CytomX Total Liab from 2010 to 2025
| CTMX Stock | USD 0.67 0.07 11.67% |
Total Liabilities | First Reported 2013-12-31 | Previous Quarter 162.4 M | Current Value 121 M | Quarterly Volatility 98.5 M |
Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.1 M or Selling General Administrative of 29.1 M, as well as many indicators such as Price To Sales Ratio of 0.6, Dividend Yield of 0.0299 or Days Sales Outstanding of 7.79. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.
CytomX | Total Liab |
Latest CytomX Therapeutics' Total Liab Growth Pattern
Below is the plot of the Total Liab of CytomX Therapeutics over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. CytomX Therapeutics' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
CytomX Total Liab Regression Statistics
| Arithmetic Mean | 189,842,466 | |
| Geometric Mean | 153,139,523 | |
| Coefficient Of Variation | 59.32 | |
| Mean Deviation | 102,562,966 | |
| Median | 240,328,459 | |
| Standard Deviation | 112,622,404 | |
| Sample Variance | 12683.8T | |
| Range | 288.2M | |
| R-Value | 0.66 | |
| Mean Square Error | 7668.9T | |
| R-Squared | 0.44 | |
| Significance | 0.01 | |
| Slope | 15,614,147 | |
| Total Sum of Squares | 190257.1T |
CytomX Total Liab History
About CytomX Therapeutics Financial Statements
CytomX Therapeutics investors use historical fundamental indicators, such as CytomX Therapeutics' Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 121 M | 240.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.